Catalyst Pharmaceuticals earnings were $197.4M for the trailing 12 months ending Mar 31, 2025, with 175% growth year over year. The latest CPRX earnings report on Mar 31, 2025 announced Q1 2025 earnings of $56.7M, up 1.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CPRX reported annual earnings of $163.9M, with 129.5% growth. The next CPRX earnings date is Aug 6, 2025.
CPRX past earnings growth
How has CPRX's earnings growth performed historically?
Catalyst Pharmaceuticals Earnings Reports & History FAQ
What were Catalyst Pharmaceuticals's earnings last quarter?
On CPRX's earnings call on Invalid Date, Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q1 2025 earnings per share (EPS) of $0.47, up 135% year over year. Total CPRX earnings for the quarter were $56.74 million. In the same quarter last year, Catalyst Pharmaceuticals's earnings per share (EPS) was $0.20.
When does Catalyst Pharmaceuticals report earnings?
The next CPRX earnings call is Invalid Date. Add CPRX to your watchlist to be reminded of Catalyst Pharmaceuticals's next earnings date.
Is Catalyst Pharmaceuticals profitable or losing money?
As of the last Catalyst Pharmaceuticals earnings report, Catalyst Pharmaceuticals is currently profitable. Catalyst Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $197.35 million, a 203.07% increase year over year.
What was CPRX's earnings growth in the past year?
As of Catalyst Pharmaceuticals's earnings date in Invalid Date, Catalyst Pharmaceuticals's earnings has grown 175% year over year. This is 163.78 percentage points higher than the US Biotechnology industry earnings growth rate of 11.22%. CPRX earnings in the past year totalled $197.35 million.
What are Catalyst Pharmaceuticals's earnings expectations?
The current EPS estimate for Catalyst Pharmaceuticals's earnings report in Invalid Date is $0.40.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.